NAS:KROS (USA)
Keros Therapeutics Inc $ 67.15 2.86 (4.45%)
Volume:
190,302
Avg Vol (1m):
194,233
Market Cap $:
1.56 Bil
Enterprise Value $:
1.42 Bil
P/E (TTM):
0.00
P/B:
10.36
Current and historical daily P/E ratio for Keros Therapeutics Inc () from 2020 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Keros Therapeutics stock (KROS) PE ratio as of Jan 25 2021 is 0.
More Details
Keros Therapeutics PE Ratio (TTM) Chart
EMBED
Keros Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 207
- 1
- 2
- 3
| Keros Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-01-25 | 0.0 | 2020-11-19 | 0.0 |
| 2021-01-22 | 0.0 | 2020-11-18 | 0.0 |
| 2021-01-21 | 0.0 | 2020-11-17 | 0.0 |
| 2021-01-20 | 0.0 | 2020-11-16 | 0.0 |
| 2021-01-19 | 0.0 | 2020-11-13 | 0.0 |
| 2021-01-15 | 0.0 | 2020-11-12 | 0.0 |
| 2021-01-14 | 0.0 | 2020-11-11 | 0.0 |
| 2021-01-13 | 0.0 | 2020-11-10 | 0.0 |
| 2021-01-12 | 0.0 | 2020-11-09 | 0.0 |
| 2021-01-11 | 0.0 | 2020-11-06 | 0.0 |
| 2021-01-08 | 0.0 | 2020-11-05 | 0.0 |
| 2021-01-07 | 0.0 | 2020-11-04 | 0.0 |
| 2021-01-06 | 0.0 | 2020-11-03 | 0.0 |
| 2021-01-05 | 0.0 | 2020-11-02 | 0.0 |
| 2021-01-04 | 0.0 | 2020-10-30 | 0.0 |
| 2021-01-01 | 0.0 | 2020-10-29 | 0.0 |
| 2020-12-31 | 0.0 | 2020-10-28 | 0.0 |
| 2020-12-30 | 0.0 | 2020-10-27 | 0.0 |
| 2020-12-29 | 0.0 | 2020-10-26 | 0.0 |
| 2020-12-28 | 0.0 | 2020-10-23 | 0.0 |
| 2020-12-24 | 0.0 | 2020-10-22 | 0.0 |
| 2020-12-23 | 0.0 | 2020-10-21 | 0.0 |
| 2020-12-22 | 0.0 | 2020-10-20 | 0.0 |
| 2020-12-21 | 0.0 | 2020-10-19 | 0.0 |
| 2020-12-18 | 0.0 | 2020-10-16 | 0.0 |
| 2020-12-17 | 0.0 | 2020-10-15 | 0.0 |
| 2020-12-16 | 0.0 | 2020-10-14 | 0.0 |
| 2020-12-15 | 0.0 | 2020-10-13 | 0.0 |
| 2020-12-14 | 0.0 | 2020-10-12 | 0.0 |
| 2020-12-11 | 0.0 | 2020-10-09 | 0.0 |
| 2020-12-10 | 0.0 | 2020-10-08 | 0.0 |
| 2020-12-09 | 0.0 | 2020-10-07 | 0.0 |
| 2020-12-08 | 0.0 | 2020-10-06 | 0.0 |
| 2020-12-07 | 0.0 | 2020-10-05 | 0.0 |
| 2020-12-04 | 0.0 | 2020-10-02 | 0.0 |
| 2020-12-03 | 0.0 | 2020-10-01 | 0.0 |
| 2020-12-02 | 0.0 | 2020-09-30 | 0.0 |
| 2020-12-01 | 0.0 | 2020-09-29 | 0.0 |
| 2020-11-30 | 0.0 | 2020-09-28 | 0.0 |
| 2020-11-27 | 0.0 | 2020-09-25 | 0.0 |
| 2020-11-26 | 0.0 | 2020-09-24 | 0.0 |
| 2020-11-25 | 0.0 | 2020-09-23 | 0.0 |
| 2020-11-24 | 0.0 | 2020-09-22 | 0.0 |
| 2020-11-23 | 0.0 | 2020-09-21 | 0.0 |
| 2020-11-20 | 0.0 | 2020-09-18 | 0.0 |
Keros Therapeutics PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NAS:URGN
NAS:ACIU
NAS:FREQ
NAS:NK
NAS:APRE
NAS:VKTX
NAS:BCEL
NAS:ANAB
NAS:SNDX
NAS:VBIV
OCSE:NOVO B
ASX:CSL
NAS:VRTX
NAS:REGN
XKRX:207940
NAS:SGEN
NAS:MRNA
NAS:ALXN
XKRX:068270
NAS:INCY
Traded in other countries
KROS.USA
Address
99 Hayden Avenue, Suite 120, Building E, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.